The experienced team at MGC Pharma believe that Phytomedicines will influence public wellbeing across the globe by successfully treating formerly unmet medical requirements and drastically improving the lives of patients.
Mr. Zomer was recruited into MGC by it’s founders at the inception of the company, and has since served in multiple roles in the company, culminating with his current role as MD and CEO. With ten years of experience in large scale projects in the Biotech and Agrotech sectors, Mr. Zomer has been crucial in moving MGC from a Cannabis Concept to a fully functioning BioPharma company with global activities. This was part of the vision that has allowed MGC to launch, and divest itself of, both a Cannabis Cosmetic company (MGC Derma) and a Lifestyle Company (MGC Nutra), which were both crucial building blocks to centralizing the company’s pharma vision and activities. Over the past year, Mr. Zomer has been crucial to solidifying the company’s standing as a leading provider of phytomedicines in several regions globally, has successfully launched a product, ArtemiC, which is proving an effective treatment against symptoms of COVID-19, backed by ongoing clinical trials. Additionally, he has put his engineering and medical background into play, and has put a significant emphasis on the company’s research and development activities, leading to possibilities of distribution and collaboration in several compelling markets around the globe.
Mr Mitchell is a corporate finance executive with over 20 years of experience in the finance and resources industries. He has been involved in the founding, financing and management of both private and publicly-listed resource companies and holds executive and non-executive directorship roles. Mr Mitchell holds a Bachelor of Economics from the University of Western Australia and is also a member of the Australian Institute of Company Directors (AICD).
Previously CEO of a leading Medical Cannabis company with a large patient base, as well as over 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles. Founded MGC Pharmaceuticals to expand into the International markets and to raise the quality of, and access to Medicinal Phytocannabinoid products to patients worldwide.
Dr Ross Walker is an eminent practicing cardiologist with over 35 years’ experience as a clinician. For the past 20 years, he has been focusing on preventative cardiology and is one of Australia’s leading preventative health experts. Considered one of the world’s best keynote speakers and life coaches, he is the author of seven best-selling books, a health presenter in the Australian Media, including regular appearances on the Nine Network’s ‘Today Show’ and ‘A Current Affair’, and Sky News, Switzer Business. He also has a weekly radio show on Sydney’s 2UE/ 4BC &2CC with other regular segments on 2UE, 6PR, 4BC and 3AW.
Stephen Parker is a seasoned executive with over thirty years’ experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier with Baring’s, Warburg’s and Apax Partners. Stephen is currently Chairman of Sareum Holdings plc and a Non-Executive Director of Eternans Limited. Stephen has a D.Phil. from Oxford University and an MBA from City University Business School.
Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours). Mr Hayes’ has also won the Daniel O’Carroll Award for Scientific Research.
Mr Hayes is currently the Asia Pacific Managing Director of Factors Group, Canada’s largest natural health company. Prior to this Mr Hayes was the Director of Sourcing and Product development at Australia’s largest natural health company, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions and managed a budget of $250m.
Mrs. Kerr has over 10 years’ experience as a Company Secretary on both private and public companies, working on acquisitions, capital raisings, IPO’s on ASX, due diligence reviews and compliance of public companies.
Mr. Lipsky was the business development director of leading Medical Cannabis company in Israel. He brings a history of production and development to the company and has been working in the Cannabis field for the past ten years.
10 years of experience in Projects Management and Business Process Design and improvement as a senior consultant for Deloitte and a Project Manager in Tel-Aviv-Jaffa municipality, Implementing complex solutions in various industries in Enterprise and SMB globally.
With a wealth of experience in multiple industries, from large scale agricultural rollouts to customer facing retail oriented product development, Itay brings a focus on streamlining systems and creating efficient operations for MGC across the company’s activities. With a passion for finding the best ways for people to work together towards achieving common goals, Itay is working with all parts of the company, both geographically and operationally to ensure MGC’s efficiency and ability to scale up in the years ahead.
Certified in Israel, with clinical experience in at the M.D. Anderson Cancer Center, Dr. Grunfeld has spent the past twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cananabis as a treatment for oncological palliative care. He has directly been involved in the licensing and care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.
Mr. Polak is a scientist who, for the last 15 years, has been working within the chemical industry in various fields including pharmaceutical, fuel, bio-fuel and 3D printing, from inception through to release to market. Mr. Polak has an MSc in Chemistry from the Hebrew University (Jerusalem).
Professor Uri Kramer, a former Director of Paediatric Epilepsy Service at Tel Aviv Sourasky Medical Centre in Tel Aviv, Israel. Professor Kramer led research regarding medical cannabis treatments for severe cases of epilepsy, where he is an acknowledged global expert. He has a wealth of experience in various fields (Neurology, Paediatric Neurology and Child Development). He advises and help direct the key strategy for the commencement of clinical trials using medicinal cannabis for severe epilepsy and nausea in Australia and in Europe. Professor Kramer was the President of the Israeli League Against Epilepsy, giving him unique insight into the daily struggles of the patients his research benefits. Currently he is a Professor of Paediatrics in Tell Aviv University.
As Head of Department of Child, Adolescent and Developmental Neurology at University Children’s Hospital, Ljubljana, Professor Neubauer is widely published and respected, and has dealt with children and adolescents in Neurological contexts for more than thirty years.
Nadya Lisovoder is an accomplished Doctor of Medicine with 15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr.Lisovoder is a regulatory expert and has been clinical adviser to public biotech companies and a range of incubator and acceleration including Furtux- a J&J Innovation and Takeda program. Nadya has managed clinical trials across multiple therapy areas in complex, multi site studies encompassing Israel, EU and the US for large Pharma companies such as Schering Plough, as well as innovative start ups. Since 2012, Dr. Lisovoder has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities,international Pharma companies, global CROs and biotech companies.
In 2016 Nadya founded Galilee Clinical Research Ltd, a multi- faceted entrepreneurial center providing regulatory consulting to support product development and prepare companies for FDA meetings and filings, providing regulatory guidance for successful implementation and regulatory compliance of clinical trial programs.
Mr. Segeve bringing years of cultivation to bear on MGC’s ambitious genetics breeding program, Elad has brought a level of professionalism to MGC’s botanical operations, initially in the company’s cultivations globally and culminating with several EU registered strains with very unique characteristics which form the core of MGC’s Botanic IP.
Karmen brings her degree in Bio-Chemistry and her experience in Genetic Molecular Biology to ensuring MGC’s Cleanroom operations, from extraction to formulation, are all under the highest level of supervision and quality control.
With a wealth of experience in the QA and QP departments of several major manufacturers in Slovenia, Sabina brings her experience and local understanding to MGC, allowing the company to ensure seamless compliance and smooth production processes.
With over 10 years experience in laboratory environments coordinating and running studies in various fields, Dr Pribošič brings valuable knowledge to running MGC’s side of all laboratory oriented experimentation and engagements. With a focus on analytical chemistry, Irena brings rigorous facility management and QC protocols to ensure MGC’s research maintains the highest levels of clarity and supervision.